Literature DB >> 18819100

Inflammatory processes of prostate tissue microenvironment drive rat prostate carcinogenesis: preventive effects of celecoxib.

Narayanan K Narayanan1, Dominick Nargi, Lori Horton, Bandaru S Reddy, Maarten C Bosland, Bhagavathi A Narayanan.   

Abstract

BACKGROUND: Prostate tissue microenvironment is susceptible to several risk factors including carcinogens, dietary factors, hormones, cytokines and growth factors that could induce chronic inflammation. Because of the difference in the serum levels and the intrinsic ability of monocytes/macrophages to cause harm, the transcriptional responses triggered by inflammatory stimuli must be controlled. Unfortunately, an in-depth association between prostate cancer and potential mediators of inflammation has not been completely investigated.
METHODS: To determine whether activated macrophage (infiltrating monocytes), iNOS and NF-kappaB are primary mediators of inflammation, besides COX-2, in prostate carcinogenesis, we examined tissue sections of rat prostate tumor induced by N-methyl-N-nitrosourea (MNU) plus testosterone in a follow-up study. We performed H&E and immunohsitochemical staining of the prostate tissue to detect specific markers of inflammation.
RESULTS: We report an increase in infiltrating monocyte, iNOS, NF-kappaBp65, VEGF and TNF-alpha at the early and advanced stages of tumor growth in MNU plus testosterone treated rats. Monocyte infiltration was often found in the stromal and perivascular regions of the DL prostate. We conclude for the first time that prostate cancer induced by MNU plus testosterone partly involves mediators of inflammation which could trigger the process of carcinogenesis and cause loss of apoptosis. Selective COX-2 inhibitor celecoxib at a dose of 500 mg/kg/bw administered for 52 weeks reduced infiltrating monocytes, inhibited iNOS, NF-kappaB p65 expression, induced apoptosis and tumor growth inhibition.
CONCLUSION: Carcinogen plus testosterone induced prostate carcinogenesis showing activation of macrophage, iNOS and NF-kappaBp65 could be prevented by celecoxib or related anti-inflammatory agents.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18819100     DOI: 10.1002/pros.20862

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  12 in total

1.  Protective effect of γ-tocopherol-enriched diet on N-methyl-N-nitrosourea-induced epithelial dysplasia in rat ventral prostate.

Authors:  Lucas D Sanches; Sergio A A Santos; Jaqueline R Carvalho; Gabriela D M Jeronimo; Wagner J Favaro; Maria D G Reis; Sérgio L Felisbino; Luis A Justulin
Journal:  Int J Exp Pathol       Date:  2013-10-29       Impact factor: 1.925

Review 2.  Vitamin D metabolism and action in the prostate: implications for health and disease.

Authors:  Srilatha Swami; Aruna V Krishnan; David Feldman
Journal:  Mol Cell Endocrinol       Date:  2011-06-01       Impact factor: 4.102

3.  Alcohol exposure in utero increases susceptibility to prostate tumorigenesis in rat offspring.

Authors:  Sengottuvelan Murugan; Changqing Zhang; Sepideh Mojtahedzadeh; Dipak K Sarkar
Journal:  Alcohol Clin Exp Res       Date:  2013-07-26       Impact factor: 3.455

4.  IL-17 Expression by macrophages is associated with proliferative inflammatory atrophy lesions in prostate cancer patients.

Authors:  Eugene V Vykhovanets; Gregory T Maclennan; Olena V Vykhovanets; Sanjay Gupta
Journal:  Int J Clin Exp Pathol       Date:  2011-08-03

5.  Antibody responses to prostate-associated antigens in patients with prostatitis and prostate cancer.

Authors:  Brett B Maricque; Jens C Eickhoff; Douglas G McNeel
Journal:  Prostate       Date:  2011-02-01       Impact factor: 4.104

6.  Comprehensive identification and modified-site mapping of S-nitrosylated targets in prostate epithelial cells.

Authors:  Ying Wai Lam; Yong Yuan; Jared Isaac; C V Suresh Babu; Jarek Meller; Shuk-Mei Ho
Journal:  PLoS One       Date:  2010-02-05       Impact factor: 3.240

Review 7.  Anti-inflammatory drugs, antioxidants, and prostate cancer prevention.

Authors:  Aditya Bardia; Elizabeth A Platz; Srinivasan Yegnasubramanian; Angelo M De Marzo; William G Nelson
Journal:  Curr Opin Pharmacol       Date:  2009-07-01       Impact factor: 5.547

8.  Modulatory effect of silymarin on inflammatory mediators in experimentally induced benign prostatic hyperplasia: emphasis on PTEN, HIF-1α, and NF-κB.

Authors:  Reem T Atawia; Hala H Mosli; Mariane G Tadros; Amani E Khalifa; Hisham A Mosli; Ashraf B Abdel-Naim
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-08-28       Impact factor: 3.000

9.  Inhibition of bladder tumor growth by chitooligosaccharides in an experimental carcinogenesis model.

Authors:  João C Fernandes; José Sereno; Patricia Garrido; Belmiro Parada; Maria F X Cunha; Flávio Reis; Manuela E Pintado; Alice Santos-Silva
Journal:  Mar Drugs       Date:  2012-12       Impact factor: 5.118

10.  HMGB1: A Promising Therapeutic Target for Prostate Cancer.

Authors:  Munirathinam Gnanasekar; Ramaswamy Kalyanasundaram; Guoxing Zheng; Aoshuang Chen; Maarten C Bosland; André Kajdacsy-Balla
Journal:  Prostate Cancer       Date:  2013-05-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.